# Microglial heterogeneity: influence of human 2D, 3D, and co-culture models on gene expression and immune function

**Authors:** Fazeleh Etebar, Anthony R. White, Hazel Quek

PMC · DOI: 10.3389/fncel.2026.1770518 · Frontiers in Cellular Neuroscience · 2026-02-11

## TL;DR

This study shows how different culture conditions affect human microglial cell diversity and immune function, revealing new cell states and signaling patterns.

## Contribution

The paper identifies novel microglial states and demonstrates how culture dimensionality and co-culture influence their heterogeneity and immune responses.

## Key findings

- Four microglial states were identified, including IFN-responsive, chemokine-enriched, metabolically active, and proliferative states.
- 3D cultures showed greater cellular diversity and metabolic activity compared to 2D cultures.
- Co-culture increased proliferative microglia and immune communication via CCL2/CCL5/CCL7, CSF1, and VEGF/FLT1 pathways.

## Abstract

Microglia, the resident immune cells of the central nervous system, exhibit substantial phenotypic and functional diversity shaped by local microenvironmental cues. While advanced in vitro human microglial models exist, the influence of culture dimensionality and cellular context on microglial state composition remains poorly defined. Here, we analyzed single-cell RNA sequencing datasets from human monocyte-derived microglia (MDMi) cultured under two-dimensional (2D) and three-dimensional (3D) monoculture, as well as 3D neural–glial co-culture conditions. Across platforms, four microglial states were identified, including interferon (IFN)-responsive, chemokine-enriched, metabolically active, and proliferative states, with pronounced environment-dependent transcriptional shifts. 2D cultures were dominated by IFN-responsive microglia characterized by elevated IFITM2 and IFITM3 expression, whereas 3D systems supported greater cellular diversity, including expanded metabolic programs and chemokine remodeling. Co-culture further increased proliferative microglia and induced immune-communication signatures involving CCL2/CCL5/CCL7, CSF1, and VEGF/FLT1 pathways. Pseudotime analysis revealed a largely linear trajectory in 2D cultures, but branching differentiation paths in 3D and co-culture systems, consistent with enhanced microglial heterogeneity. Benchmarking against human microglial reference signatures demonstrated broader and stronger overlap in 3D-based models, with homeostatic and disease-associated modules engaged in a context-specific manner. These findings demonstrate that culture architecture is a major determinant of microglial identity and immune responsiveness; and highlight the value of single-cell datasets to uncover previously underappreciated microglial states with relevance to human neuroimmune biology.

## Linked entities

- **Genes:** IFITM2 (interferon induced transmembrane protein 2) [NCBI Gene 10581], IFITM3 (interferon induced transmembrane protein 3) [NCBI Gene 10410]
- **Proteins:** CCL2 (C-C motif chemokine ligand 2), CCL5 (C-C motif chemokine ligand 5), CCL7 (C-C motif chemokine ligand 7), CSF1 (colony stimulating factor 1), VEGFA (vascular endothelial growth factor A), FLT1 (fms related receptor tyrosine kinase 1)

## Full-text entities

- **Genes:** IGSF21 (immunoglobin superfamily member 21) [NCBI Gene 84966], CXCL5 (C-X-C motif chemokine ligand 5) [NCBI Gene 6374] {aka ENA-78, SCYB5}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, IL34 (interleukin 34) [NCBI Gene 146433] {aka C16orf77, IL-34}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, HEXB (hexosaminidase subunit beta) [NCBI Gene 3074] {aka ENC-1AS, HEL-248, HEL-S-111}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, THBS1 (thrombospondin 1) [NCBI Gene 7057] {aka THBS, THBS-1, TSP, TSP-1, TSP1}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, ROBO4 (roundabout guidance receptor 4) [NCBI Gene 54538] {aka AOVD3, ECSM4, MRB}, GEM (GTP binding protein overexpressed in skeletal muscle) [NCBI Gene 2669] {aka KIR}, TMEM37 (transmembrane protein 37) [NCBI Gene 140738] {aka PR, PR1}, SELENOP (selenoprotein P) [NCBI Gene 6414] {aka SELP, SEPP, SEPP1, SeP}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, NUPR1 (nuclear protein 1, transcriptional regulator) [NCBI Gene 26471] {aka COM1, P8}, RSAD2 (radical S-adenosyl methionine domain containing 2) [NCBI Gene 91543] {aka SAND, cig33, cig5, vig1}, PERM1 (PPARGC1 and ESRR induced regulator, muscle 1) [NCBI Gene 84808] {aka C1orf170}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, HS3ST2 (heparan sulfate-glucosamine 3-sulfotransferase 2) [NCBI Gene 9956] {aka 30ST2, 3OST2}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, CCL7 (C-C motif chemokine ligand 7) [NCBI Gene 6354] {aka FIC, MARC, MCP-3, MCP3, NC28, SCYA6}, TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209] {aka AD17, PLOSL2, TREM-2, Trem2a, Trem2b, Trem2c}, IFITM3 (interferon induced transmembrane protein 3) [NCBI Gene 10410] {aka 1-8U, DSPA2b, IP15}, ND2 (NADH dehydrogenase subunit 2) [NCBI Gene 4536] {aka MTND2}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, CAMP (cathelicidin antimicrobial peptide) [NCBI Gene 820] {aka CAP-18, CAP18, CRAMP, FALL-39, FALL39, HSD26}, MEF2C (myocyte enhancer factor 2C) [NCBI Gene 4208] {aka C5DELq14.3, DEL5q14.3, NEDHSIL}, CCL17 (C-C motif chemokine ligand 17) [NCBI Gene 6361] {aka A-152E5.3, ABCD-2, SCYA17, TARC}, HIC1 (HIC ZBTB transcriptional repressor 1) [NCBI Gene 3090] {aka ZBTB29, ZNF901, hic-1}, KIFC1 (kinesin family member C1) [NCBI Gene 3833] {aka HSET, KNSL2}, LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) [NCBI Gene 10894] {aka CRSBP-1, HAR, LYVE-1, XLKD1}, APOC1 (apolipoprotein C1) [NCBI Gene 341] {aka APOC1B, Apo-CI, ApoC-I, apo-CIB, apoC-IB}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, CCL22 (C-C motif chemokine ligand 22) [NCBI Gene 6367] {aka A-152E5.1, ABCD-1, DC/B-CK, MDC, SCYA22, STCP-1}, CST3 (cystatin C) [NCBI Gene 1471] {aka ADLDWA, ARMD11, HEL-S-2}, MX2 (MX dynamin like GTPase 2) [NCBI Gene 4600] {aka MXB}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, SDC2 (syndecan 2) [NCBI Gene 6383] {aka CD362, HSPG, HSPG1, SYND2}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, FCGBP (Fc gamma binding protein) [NCBI Gene 8857] {aka FC(GAMMA)BP}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, TYMS (thymidylate synthetase) [NCBI Gene 7298] {aka DKCD, HST422, TMS, TS}, MKI67 (marker of proliferation Ki-67) [NCBI Gene 4288] {aka KIA, MIB-, MIB-1, PPP1R105}, FABP4 (fatty acid binding protein 4) [NCBI Gene 2167] {aka A-FABP, AFABP, ALBP, HEL-S-104, aP2}, FOLR2 (folate receptor beta) [NCBI Gene 2350] {aka BETA-HFR, FBP, FBP/PL-1, FR-BETA, FR-P3, FRbeta}, CCL13 (C-C motif chemokine ligand 13) [NCBI Gene 6357] {aka CKb10, MCP-4, NCC-1, NCC1, SCYA13, SCYL1}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, C1QB (complement C1q B chain) [NCBI Gene 713] {aka C1QD2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, F13A1 (coagulation factor XIII A chain) [NCBI Gene 2162] {aka F13A}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}
- **Diseases:** ALS (MESH:D000690), neuroinflammation (MESH:D000090862), AD (MESH:D000544), neurotoxic (MESH:D020258), PD (MESH:D010300), neurodegeneration (MESH:D019636), injury (MESH:D014947), inflammatory (MESH:D007249)
- **Chemicals:** RPMI-1640 medium (-), lipid (MESH:D008055), phospholipid (MESH:D010743)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932485/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932485/full.md

## References

93 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932485/full.md

---
Source: https://tomesphere.com/paper/PMC12932485